TY - JOUR
T1 - The role of dopaminergic agents in improving quality of life in major depressive disorder
AU - Ishak, Waguih William
AU - Davis, Michael
AU - Jeffrey, Jessica
AU - Balayan, Konstantin
AU - Pechnick, Robert N.
AU - Bagot, Kara
AU - Rapaport, Mark Hyman
N1 - Funding Information:
Dr. Rapaport has served as a consultant for and received research grant support from the National Institute of Mental Health and received research grant support from the National Center for Complementary and Alternative Medicine.
Funding Information:
Dr. IsHak has received an investigator-initiated research grant from Pfizer.
PY - 2009/12
Y1 - 2009/12
N2 - Quality of life (QOL) is greatly diminished in patients with major depressive disorder (MDD) before treatment. This deficit persists even when patients are in remission; thus, interventions are needed to improve QOL. This article reviews QOL impairment in MDD and the cost of impairment, then summarizes the empiric literature on the effects of dopaminergic agents on QOL in patients with MDD. Studies were identified through a MEDLINE search from the past 35 years (1974-2009) using key terms "quality of life," "major depression," and "major depressive disorder," and "dopaminergic," "bupropion," or "modafinil." A total of 47 studies were included in this review. A brief overview of the relationship between QOL and MDD is presented, followed by a review of dopaminergic agent chemistry, mechanism of action, use, and trials conducted to investigate agents' effects on QOL. Preliminary evidence suggests dopaminergic agents may have a positive effect on QOL for patients with MDD. Prospective, randomized, double-blind, placebo-controlled studies are needed to extend these findings.
AB - Quality of life (QOL) is greatly diminished in patients with major depressive disorder (MDD) before treatment. This deficit persists even when patients are in remission; thus, interventions are needed to improve QOL. This article reviews QOL impairment in MDD and the cost of impairment, then summarizes the empiric literature on the effects of dopaminergic agents on QOL in patients with MDD. Studies were identified through a MEDLINE search from the past 35 years (1974-2009) using key terms "quality of life," "major depression," and "major depressive disorder," and "dopaminergic," "bupropion," or "modafinil." A total of 47 studies were included in this review. A brief overview of the relationship between QOL and MDD is presented, followed by a review of dopaminergic agent chemistry, mechanism of action, use, and trials conducted to investigate agents' effects on QOL. Preliminary evidence suggests dopaminergic agents may have a positive effect on QOL for patients with MDD. Prospective, randomized, double-blind, placebo-controlled studies are needed to extend these findings.
UR - http://www.scopus.com/inward/record.url?scp=72849120467&partnerID=8YFLogxK
U2 - 10.1007/s11920-009-0076-z
DO - 10.1007/s11920-009-0076-z
M3 - Review article
C2 - 19909674
AN - SCOPUS:72849120467
SN - 1523-3812
VL - 11
SP - 503
EP - 508
JO - Current Psychiatry Reports
JF - Current Psychiatry Reports
IS - 6
ER -